What are the effects of abiraterone acetate as adjunct to androgen deprivation therapy (ADT) for men with metastatic hormone-sensitive prostate cancer?

Cochrane Clinical Answers ◽

10.1002/cca.3570 ◽

2021 ◽

Author(s):

Sera Tort ◽

Marta Briarava

Keyword(s):

Prostate Cancer ◽

Androgen Deprivation Therapy ◽

Abiraterone Acetate ◽

Androgen Deprivation ◽

Hormone Sensitive

Download Full-text

Clinical Outcomes of First-line Abiraterone Acetate or Enzalutamide for Metastatic Castration-resistant Prostate Cancer After Androgen Deprivation Therapy + Docetaxel or ADT Alone for Metastatic Hormone-sensitive Prostate Cancer

Clinical Genitourinary Cancer ◽

10.1016/j.clgc.2017.12.012 ◽

2018 ◽

Vol 16 (2) ◽

pp. 130-134 ◽

Author(s):

Edoardo Francini ◽

Steven Yip ◽

Shubidito Ahmed ◽

Haocheng Li ◽

Luke Ardolino ◽

...

Keyword(s):

Prostate Cancer ◽

Clinical Outcomes ◽

Androgen Deprivation Therapy ◽

Abiraterone Acetate ◽

Androgen Deprivation ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant ◽

Hormone Sensitive

Download Full-text

Comparison of abiraterone acetate and docetaxel with androgen deprivation therapy in high-volume metastatic hormone-sensitive prostate cancer (mHSPC): An updated network meta-analysis and cost minimization analysis in China.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.e17008 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. e17008-e17008

Author(s):

Xin Hu ◽

Xingxing Yao ◽

Chaoyun Li ◽

Yanjun Liu ◽

Tengbin Xiong ◽

...

Keyword(s):

Prostate Cancer ◽

Androgen Deprivation Therapy ◽

Cost Minimization ◽

Meta Analysis ◽

High Volume ◽

Abiraterone Acetate ◽

Androgen Deprivation ◽

Cost Minimization Analysis ◽

Hormone Sensitive

Download Full-text

Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer

Cochrane Database of Systematic Reviews ◽

10.1002/14651858.cd013245.pub2 ◽

2020 ◽

Author(s):

Niranjan J Sathianathen ◽

Makinna C Oestreich ◽

Sarah Jane Brown ◽

Shilpa Gupta ◽

Badrinath R Konety ◽

...

Keyword(s):

Prostate Cancer ◽

Androgen Deprivation Therapy ◽

Abiraterone Acetate ◽

Androgen Deprivation ◽

Hormone Sensitive

Download Full-text

Benefit Of Abiraterone Acetate Plus Prednisone (AA+P) Added To Androgen Deprivation Therapy (ADT) In Patients With High-Risk, Newly Diagnosed Metastatic Hormone-Sensitive Prostate Cancer (MHSPC): Post Hoc Analysis Of EQ-5D-5L From The Latitude Study

Value in Health ◽

10.1016/j.jval.2018.04.317 ◽

2018 ◽

Vol 21 ◽

pp. S38 ◽

Author(s):

H Metin ◽

K McQuarrie ◽

P Thilakarathne ◽

J Diels ◽

T Ito ◽

...

Keyword(s):

Prostate Cancer ◽

High Risk ◽

Androgen Deprivation Therapy ◽

Abiraterone Acetate ◽

Androgen Deprivation ◽

Newly Diagnosed ◽

Post Hoc Analysis ◽

Hormone Sensitive ◽

Download Full-text

Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer

Cochrane Database of Systematic Reviews ◽

10.1002/14651858.cd013245 ◽

2019 ◽

Author(s):

Niranjan J Sathianathen ◽

Philipp Dahm ◽

Sarah Jane Brown ◽

Makinna Oestreich ◽

Shilpa Gupta ◽

...

Keyword(s):

Prostate Cancer ◽

Androgen Deprivation Therapy ◽

Abiraterone Acetate ◽

Androgen Deprivation ◽

Hormone Sensitive

Download Full-text

Abiraterone acetate versus nonsteroidal antiandrogen with androgen deprivation therapy for high‐risk metastatic hormone‐sensitive prostate cancer

The Prostate ◽

10.1002/pros.24243 ◽

2021 ◽

Author(s):

Takafumi Yanagisawa ◽

Takahiro Kimura ◽

Keiichiro Mori ◽

Hirotaka Suzuki ◽

Takayuki Sano ◽

...

Keyword(s):

Prostate Cancer ◽

High Risk ◽

Androgen Deprivation Therapy ◽

Abiraterone Acetate ◽

Androgen Deprivation ◽

Hormone Sensitive

Download Full-text

Abiraterone acetate/androgen deprivation therapy combination versus docetaxel/androgen deprivation therapy combination in advanced hormone-sensitive prostate cancer: a network meta-analysis on safety and efficacy

Current Medical Research and Opinion ◽

10.1080/03007995.2018.1447450 ◽

2018 ◽

Vol 34 (5) ◽

pp. 903-910 ◽

Author(s):

Loay Kassem ◽

Kyrillus S. Shohdy ◽

Omar Abdel-Rahman

Keyword(s):

Prostate Cancer ◽

Androgen Deprivation Therapy ◽

Meta Analysis ◽

Abiraterone Acetate ◽

Androgen Deprivation ◽

Safety And Efficacy ◽

Hormone Sensitive

Download Full-text

Faculty Opinions recommendation of Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naïve Prostate Cancer: A Systematic Review and Network Meta-analysis.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.732006685.793538242 ◽

2017 ◽

Author(s):

Michael Glode

Keyword(s):

Prostate Cancer ◽

Systematic Review ◽

High Risk ◽

Androgen Deprivation Therapy ◽

Meta Analysis ◽

Abiraterone Acetate ◽

Androgen Deprivation

Download Full-text

Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy

European Urology ◽

10.1016/j.eururo.2021.05.016 ◽

2021 ◽

Author(s):

Christopher J. Sweeney ◽

Andrew J. Martin ◽

Martin R. Stockler ◽

Stephen Begbie ◽

Kim N. Chi ◽

...

Keyword(s):

Prostate Cancer ◽

Overall Survival ◽

Androgen Deprivation Therapy ◽

Androgen Deprivation ◽

Hormone Sensitive

Download Full-text

Prognostic role of the duration of response to androgen deprivation therapy in patients with metastatic castration resistant prostate cancer treated with enzalutamide or abiraterone acetate

Prostate Cancer and Prostatic Diseases ◽

10.1038/s41391-021-00336-1 ◽

2021 ◽

Author(s):

Rosario F. Di Stefano ◽

Marcello Tucci ◽

Fabio Turco ◽

Alessandro Samuelly ◽

Maristella Bungaro ◽

...

Keyword(s):

Prostate Cancer ◽

Androgen Deprivation Therapy ◽

Abiraterone Acetate ◽

Androgen Deprivation ◽

Castration Resistant Prostate Cancer ◽

Prognostic Role ◽

Castration Resistant ◽

Duration Of Response

Download Full-text